Clinical Trials Directory

Trials / Completed

CompletedNCT04653831

Treatment With Pirfenidone for COVID-19 Related Severe ARDS

Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
26 (actual)
Sponsor
Soroka University Medical Center · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

A randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per nasogastric tube or orally as 801mg TID for 4 weeks in addition to Standard of Care (SoC), compared to SoC alone, in a population of COVID-19 induced severe ARDS. Patients will be randomized according to 1:1 ratio to one of the trial arms: Pirfenidone (intervention arm) or SoC (control arm).

Detailed description

The objective of the trial is to evaluate the safety and efficacy of treatment with Pirfenidone vs SoC in COVID-19 induced severe Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation. Following initial diagnosis of COVID-19, severe ARDS patient will be admitted to a dedicated intensive care unit (ICU) at Soroka University Medical Center (Day 0). Upon admission, patients will be randomized according to 1:1 ratio to one of the trial arms and receive either Pirfenidone 2,403mg administered through nasogastric tube as 801mg TID (intervention arm) plus SoC or only SoC treatment (control arm). Patients' vital signs (temperature, blood pressure, pulse rate per minute, breath rate per minute, oxygen saturation) urine output, ventilation settings, and respiratory parameters will be monitored according to SoC. Symptom will be captured daily from patients as well as adverse events (AEs) assessment and recording of the need for any supportive care during the period of ICU admission.

Conditions

Interventions

TypeNameDescription
DRUGPirfenidoneTreatment with Pirfenidone as mentioned in the experimental arm description.
OTHERStandard of careTreatment with SoC as mentioned in the control arm description.

Timeline

Start date
2020-11-08
Primary completion
2022-12-31
Completion
2022-12-31
First posted
2020-12-04
Last updated
2023-05-23

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT04653831. Inclusion in this directory is not an endorsement.